ARCHIVES

As FDA Weighs its Options on Morcellation, Debate Erupts Over Harvard Device Study

This article is from The Cancer Letter archive.

Vol. 40 No. 44 | November 21, 2014

Download PDF Visit The Full Archive

Related Articles

DCT Advisors Okay Two New RFA Concepts In Clinical Research, Biodiversity Groups

November 8, 1991

Dole to Press HCFA On Community DRG Exemptions, Calls For Meeting TO Assess Problems

March 16, 1984

Groups’ Growth, Impact Shown by Five-Year Data

March 3, 1978

NCI To Test 5,000 DC-Area Jews To Determine Risk Of BRCA 1 Mutation

October 6, 1995

Boyd’s Rebuttal to DePinho’s Letter to the AAUP

May 30, 2014

NCI’s use of Cancer Dialogue for biospecimen network blueprint raises legal, procedural questions.

December 12, 2003